ABSTRACT
Avoidant/Restrictive Food Intake Disorder and misophonia seem to be overrepresented in autism spectrum disorder. Literature is mute on psychopharmacotherapy in these complex presentations. Here, authors report on a challenging case of low-functioning ASD child with comorbid ARFID and misophonia that responded favorably to a low-dose risperidone. This is followed by a brief discussion of purported pharmacodynamic mechanisms and relevant literature.
Subject(s)
Autism Spectrum Disorder , Autistic Disorder , Avoidant Restrictive Food Intake Disorder , Feeding and Eating Disorders , Autism Spectrum Disorder/complications , Autism Spectrum Disorder/drug therapy , Autistic Disorder/drug therapy , Child , Humans , RisperidoneABSTRACT
ABSTRACT: Burgeoning body of evidence from neuroscience is pouring in highlighting a potential association between gut microbiota with the pathophysiology of depression and anxiety. Manipulation of gut microbiota may be then useful to decode this role and to provide novel therapeutics for major depressive disorder (MDD), developing microbiota-related biomarkers to stratify patients at risk and to delineate more homogeneous biotypes of MDD.
